Your browser doesn't support javascript.
Toward Next Generation Lateral Flow Assays: Integration of Nanomaterials.
Sena-Torralba, Amadeo; Álvarez-Diduk, Ruslan; Parolo, Claudio; Piper, Andrew; Merkoçi, Arben.
  • Sena-Torralba A; Nanobioelectronics & Biosensors Group, Institut Català de Nanociència I Nanotecnologia (ICN2), CSIC and The Barcelona Institute of Science and Technology (BIST), Campus UAB, Bellaterra, 08193 Barcelona, Spain.
  • Álvarez-Diduk R; Instituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM), Universitat Politècnica de València, Universitat de València, Camino de Vera s/n, 46022 Valencia, Spain.
  • Parolo C; Nanobioelectronics & Biosensors Group, Institut Català de Nanociència I Nanotecnologia (ICN2), CSIC and The Barcelona Institute of Science and Technology (BIST), Campus UAB, Bellaterra, 08193 Barcelona, Spain.
  • Piper A; Barcelona Institute for Global Health (ISGlobal) Hospital Clínic-Universitat de Barcelona, Carrer del Rosselló 132, 08036 Barcelona, Spain.
  • Merkoçi A; Nanobioelectronics & Biosensors Group, Institut Català de Nanociència I Nanotecnologia (ICN2), CSIC and The Barcelona Institute of Science and Technology (BIST), Campus UAB, Bellaterra, 08193 Barcelona, Spain.
Chem Rev ; 122(18): 14881-14910, 2022 09 28.
Article in English | MEDLINE | ID: covidwho-2016511
ABSTRACT
Lateral flow assays (LFAs) are currently the most used point-of-care sensors for both diagnostic (e.g., pregnancy test, COVID-19 monitoring) and environmental (e.g., pesticides and bacterial monitoring) applications. Although the core of LFA technology was developed several decades ago, in recent years the integration of novel nanomaterials as signal transducers or receptor immobilization platforms has brought improved analytical capabilities. In this Review, we present how nanomaterial-based LFAs can address the inherent challenges of point-of-care (PoC) diagnostics such as sensitivity enhancement, lowering of detection limits, multiplexing, and quantification of analytes in complex samples. Specifically, we highlight the strategies that can synergistically solve the limitations of current LFAs and that have proven commercial feasibility. Finally, we discuss the barriers toward commercialization and the next generation of LFAs.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pesticides / Nanostructures / Metal Nanoparticles / COVID-19 Type of study: Diagnostic study Limits: Humans Language: English Journal: Chem Rev Year: 2022 Document Type: Article Affiliation country: Acs.chemrev.1c01012

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pesticides / Nanostructures / Metal Nanoparticles / COVID-19 Type of study: Diagnostic study Limits: Humans Language: English Journal: Chem Rev Year: 2022 Document Type: Article Affiliation country: Acs.chemrev.1c01012